Home Your basket
• Explorations of the velum...
   Price 14.00 €
• Complete branchial cleft ...
   Price 5.50 €
• Adolescence and cochlear ...
   Price 10.50 €
• Which face lift for which...
   Price 14.00 €
• Therapeutic management of...
   Price 10.50 €
• Management of labial inco...
   Price 10.50 €
• Silent Sinus Syndrome – T...
   Price 8.50 €
• Surgery for hyperthyroidi...
   Price 5.50 €
• Interest of the cervical ...
   Price 10.50 €
• Temporary loss of visual ...
   Price 8.50 €
• Parapharyngeal lymph node...
   Price 8.50 €
• Endoscopic anatomy of the...
   Price 10.50 €
• Choanal atresia: therapeu...
   Price 10.50 €
• Cholesterol granuloma of ...
   Price 8.50 €
• Zenker’s diverticulum in ...
   Price 8.50 €
• Vestibular neuritis: Eval...
   Price 14.00 €
• Unilateral endolymphatic ...
   Price 10.50 €
• Hearing aid : practical a...
   Price 8.50 €
• Malignant melanoma of the...
   Price 10.50 €
• Speech intelligibility in...
   Price 10.50 €
• ENT localisation of amylo...
   Price 15.00 €
• Aging and life quality: A...
   Price 12.50 €
• Hearing results in stapes...
   Price 10.50 €
• Mucus physiopathology, up...
   Price 12.50 €
• Autologous bone pate in m...
   Price 10.50 €
• "Endolymphatic" cochleo-v...
   Price 10.50 €
• Advantages of combined th...
   Price 10.50 €
• Dermatofibrosarcoma protu...
   Price 10.50 €
• Medical rhinoplasty conce...
   Price 14.00 €
• Neuroplasticity in the au...
   Price 10.50 €
• Delayed facial palsy afte...
   Price 8.50 €
• Pre-Congress of the Ameri...
   Price 8.50 €
• Lifting of the oval face ...
   Price 10.50 €
• Importance of a molding n...
   Price 10.50 €
• Outcome of surgical and a...
   Price 10.50 €
• Epidemiology of paediatri...
   Price 10.50 €
• Ethmoid-nasal meningioma ...
   Price 10.00 €
• A retrospective study of ...
   Price 10.50 €
• Attention deficit disorde...
   Price 10.50 €
• Sentinel lymph node biops...
   Price 15.00 €
• Characteristics of the co...
   Price 8.50 €
• Modified butterfly cartil...
   Price 10.50 €
• The role of larynx kinest...
   Price 10.50 €
• Diagnosis of non organic ...
   Price 8.50 €
• Management of a huge amel...
   Price 5.50 €
• Quality of life evaluatio...
   Price 10.50 €
• Facial nerve monitoring i...
   Price 10.50 €
• Multiple intracranial epi...
   Price 14.00 €
• Vascular tumors of the n...
   Price 10.50 €
• Thyroid papillary microca...
   Price 10.50 €
• Navigation in head and ne...
   Price 10.50 €
• Voice handicap evaluation...
   Price 10.50 €
• The place of speech thera...
   Price 8.50 €
• Fungal sinusitis: Report ...
   Price 10.50 €
• Seven cases of inverted n...
   Price 10.50 €
• A case of nasal foreign b...
   Price 8.50 €
• A schwannoma of the hypog...
   Price 8.50 €
• Interest of peri-operativ...
   Price 10.50 €
• Impaired laryngeal mobili...
   Price 10.50 €
• Endoscopic endonasal surg...
   Price 8.50 €
• Functional comparison of ...
   Price 14.00 €
• Case report on a nasal gl...
   Price 5.50 €
• A survey of current wound...
   Price 5.50 €
• Voice-breaking in adolesc...
   Price 10.50 €
• Allergic and pneumologic ...
   Price 8.50 €
• Combined induction chemot...
   Price 10.50 €
• Usher type I syndrome in ...
   Price 10.50 €
• Clinical implementation o...
   Price 5.50 €
• Notes on voice and speech...
   Price 8.50 €
• Validity of cervical ausc...
   Price 12.00 €
• Sarcomatoid carcinomas of...
   Price 10.50 €
• A study of peristomal rec...
   Price 5.50 €
• Central and peripherical ...
   Price 8.50 €
• Benign tumors of the nasa...
   Price 14.00 €

Total Order 746.50 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 4 - 2008 o

OTONEUROLOGY

Disability in patients with Menière’s disease following the use of two different treatment modalities: Betahistine and intratympanic gentamicin


Authors : Enrique-Gonzalez A, Sánchez-Ferrándiz N, Pérez-Fernández N. (Pamplona)

Ref. : Rev Laryngol Otol Rhinol. 2008;129,4:249-254.

Article published in english
Downloadable PDF document english



Summary : Objective: The objective of this study was to assess the level of residual disability and handicap in patients with Menière’s disease (MD) that were free of new vertigo spells 2 years after having been administered treatment with either oral medication or with intratympanic gentamcin. Setting: University hospital. Tertiary medical center. Material and method: 40 patients with MD were included in this study, of which 20 were treated with oral medication (betahistine) and 20 with intratympanic gentamicin; intratympanic gentamicin was for patients considered failures for the oral medication treatment. All of them are free of new vertigo in the 16-24 month period after beginning the treatment. They were matched by age and disease duration. Disability and handicap were assessed with conventional questionnaires at the time of inclusion and 2 years after beginning oral medication or ended the intratympanic gentamicin treatment. According to the treatment two groups were created: oral medication treatment and intratympanic gentamicin treatment. Results: The amount of disability before treatment was higher in patients treated with intratympanic gentamicin than in those under oral medication; However, after treatment when no more vertigo spells takes place, this disability is significantly reduced and becomes similar for both groups of patients. In patients treated with oral medication the items reflecting the intensity of vertigo spell, the impact of vertigo in daily activities, the perception of quality of life and level of somatization do not show a significant reduction. Conclusion: The number or frequency of vertigo spells are very relevant for the process of disability and handicap of patients with MD when that is low or when oral medication is sufficient to eliminate vertigo spells. However when that number is high and the only possibility to arrest those vertigo spells is the use of intratympanic gentamicin, fear of vertigo must be considered as an associated problem for the patient.

Price : 10.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE